These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12197546)

  • 21. Ophthalmic drug products for over-the-counter human use; final monograph; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Feb; 68(33):7919-21. PubMed ID: 12593411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 23. Rx-to-OTC switch movement.
    Rosenau PV
    Med Care Rev; 1994; 51(4):429-66. PubMed ID: 10139533
    [No Abstract]   [Full Text] [Related]  

  • 24. Rising drug costs prompt new uses for old pills.
    Opar A
    Nat Med; 2006 Dec; 12(12):1333. PubMed ID: 17151672
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(27):5942-3. PubMed ID: 11837282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescription to over-the-counter switch: a regulatory perspective.
    Juhl RP
    Clin Ther; 1998; 20 Suppl C():C111-7. PubMed ID: 9915097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rx-to-OTC shift: not for these widely used drugs.
    Chase SL
    RN; 1995 Jan; 58(1):67. PubMed ID: 7624708
    [No Abstract]   [Full Text] [Related]  

  • 28. Direct-to-OTC marketing of drugs: possible approaches.
    Mahinka SP; Bierman ME
    Food Drug Law J; 1995; 50(1):49-63. PubMed ID: 10342985
    [No Abstract]   [Full Text] [Related]  

  • 29. Rx drugs switched to OTC.
    FDA Drug Bull; 1983 Nov; 13(3):29-30. PubMed ID: 6653955
    [No Abstract]   [Full Text] [Related]  

  • 30. An update on the therapeutic orphan.
    Wilson JT
    Pediatrics; 1999 Sep; 104(3 Pt 2):585-90. PubMed ID: 10469794
    [No Abstract]   [Full Text] [Related]  

  • 31. Rx-to-OTC switches: trends and factors underlying success.
    Mahecha LA
    Nat Rev Drug Discov; 2006 May; 5(5):380-5. PubMed ID: 16604099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
    Shih YC; Prasad M; Luce BR
    Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?
    Moxley JH; Yingling GL; Edwards CC
    Fed Proc; 1973 Apr; 32(4):1435-7. PubMed ID: 4701750
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA considers OTC drug labeling reform.
    Am Pharm; 1995 Nov; NS35(11):5-6. PubMed ID: 8533722
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA user fees approved.
    Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous Cetirizine (Quzyttir) for Acute Urticaria.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):55-56. PubMed ID: 32324180
    [No Abstract]   [Full Text] [Related]  

  • 38. Is three a crowd or company?: Behind-the-counter drugs.
    Barth AS
    Food Drug Law J; 2008; 63(4):865-89. PubMed ID: 19601386
    [No Abstract]   [Full Text] [Related]  

  • 39. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
    Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
    Trygstad TK; Hansen RA; Wegner SE
    J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.